Pharsight

Drugs that contain Emtricitabine; Tenofovir Disoproxil Fumarate

1. Truvada patents expiration

TRUVADA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5814639 GILEAD Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Sep, 2015

(8 years ago)

US5914331 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jul, 2017

(6 years ago)

US5922695 GILEAD Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jul, 2017

(6 years ago)

US5977089 GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5935946 GILEAD Nucleotide analog composition and synthesis method
Jul, 2017

(6 years ago)

US6703396 GILEAD Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Mar, 2021

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5814639

(Pediatric)

GILEAD Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
Mar, 2016

(8 years ago)

US6043230 GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jul, 2017

(6 years ago)

US5914331

(Pediatric)

GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Jan, 2018

(6 years ago)

US5935946

(Pediatric)

GILEAD Nucleotide analog composition and synthesis method
Jan, 2018

(6 years ago)

US5922695

(Pediatric)

GILEAD Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
Jan, 2018

(6 years ago)

US5977089

(Pediatric)

GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US6043230

(Pediatric)

GILEAD Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability
Jan, 2018

(6 years ago)

US6642245 GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
Nov, 2020

(3 years ago)

US6642245

(Pediatric)

GILEAD Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
May, 2021

(2 years ago)

US6703396

(Pediatric)

GILEAD Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
Sep, 2021

(2 years ago)

US9744181 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US8592397 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US8716264 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US9457036 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(3 months ago)

US8716264

(Pediatric)

GILEAD Compositions and methods for combination antiviral therapy
Jul, 2024

(2 months from now)

Market Authorisation Date: 10 March, 2016

Treatment: Prophylaxis of hiv-1 infection; Method of treatment of adults infected with hiv-1; Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment o...

Dosage: TABLET;ORAL

How can I launch a generic of TRUVADA before it's drug patent expiration?
More Information on Dosage

TRUVADA family patents

Family Patents